retatrutide type 2 diabetes phase 2 trial 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending ESC 2024: Retatrutide improves lipid

Early Phase 2 clinical data, including results published in the New England Journal of Medicine in 2023, has shown considerable promise, with participants achieving substantial reductions in body weight

Stay Hydrated : Sipping water or ginger tea can help settle your stomach

Taspoglutide GLP-1 analogs can be effectively modified by incorporating alpha-aminoisobutyric acid (Aib) in place of Ala at the 8th position and Gly at the 35th position (Fig

Despite the limitations, these data suggest that long term therapy is not associated with durable weight loss with withdrawal of the medication and supports guidelines for extended therapy

DAscanio AM, Mullally JA, Frishman WH

Its innovative triple-receptor mechanism has positioned Retatrutide as a significant focus in modern metabolic and peptide research applications